Head-to-head dispatch
Found vs Hims & Hers
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
The widest medication bench in the ranking — compounded, six brand-name products and oral orforglipron — priced off a membership rather than a sticker.
Marked down on: The $99/mo headline is a longer-plan floor — Found's own FAQ says the 3, 6 and 12-month plans are what keep the monthly cost down, so month-to-month costs meaningfully more
Desk Score
Mass-market app-first program with nationwide polish — tirzepatide pricing disclosure lags the ranking.
Marked down on: Tirzepatide pricing inconsistently disclosed
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Found takes this head-to-head with the higher Desk Score, 81/100 (B−) against 76/100 (C) for Hims & Hers. Hims & Hers still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Found
81/100
B−
Hims & Hers
76/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Found | Hims & Hers |
|---|---|---|
| Semaglutide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still precedes a ~$30 per-visit copay | $199/mo |
| Tirzepatide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name | Yes | Compounded only |
| Oral option | Yes | Injectable only |
| Best for | People who want insurance run against their clinical visits and a clinician free to move them between compounded, brand-name and oral routes. | People who want a familiar consumer-brand app experience and don't need tirzepatide. |
| Desk Score | 81/100B− | 76/100C |
The verdict
Desk pick — FoundFound takes this head-to-head with the higher Desk Score, 81/100 (B−) against 76/100 (C) for Hims & Hers. Hims & Hers still holds its ground where its strengths line up with yours.
Choose Found if…
People who want insurance run against their clinical visits and a clinician free to move them between compounded, brand-name and oral routes.
$289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still precedes a ~$30 per-visit copay sema · $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules tirz · All 50 states
Choose Hims & Hers if…
People who want a familiar consumer-brand app experience and don't need tirzepatide.
$199/mo sema · Not disclosed tirz · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Found · Hims & Hers.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Found vs CoreAge Rx
- Hims & Hers vs Vaylen
- Found vs Strut Health
- Hims & Hers vs Ondra Health
- Found vs Invigor Medical
- Hims & Hers vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.